Leukemia

Leukemia

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

34 Clinical Trials
Leukemia NA Accepting Patients
nct/study# NCT03258931 / ARO-021

Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in ACTIVEly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

Learn More
Leukemia Phase II Accepting Patients
nct/study# NCT04093570 / ASTX727-06

An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Learn More
Leukemia Phase I Accepting Patients
nct/study# NCT04310592 / CYNK-001-AML-001

A phase I multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with ACTIVEly diagnosed primary or secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease (MRD)

Learn More
Leukemia Phase III Accepting Patients
nct/study# NCT03165734 / PAC203

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/ìL)(PACIFICA)

Learn More
Leukemia Phase III Accepting Patients
nct/study# COMPASSIONATE-USE-PACRITINIB

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Learn More
Leukemia Phase I Accepting Patients
nct/study# NCT03915379 / JNJ-67571244-AML-1001

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.